Struggling Ottawa medical device firm Annidis (TSX-V: RHA) said it shipped 15 units of its eye-care imaging technology to its Chinese distribution partner and major shareholder during the second quarter, leading to a dramatic jump in revenues.
The company recorded $786,279 in revenue, up 476 per cent from a year earlier when it failed to make a sale in the quarter.
Annidis also slashed its operating expenses by 27 per cent in the quarter by reducing R&D spending. Combined with the higher sales, the company reduced its net loss to $698,261 for the quarter, an improvement on the $1.29 million loss it recorded a year earlier.
(Sponsored)
Invest with confidence: Hydro Ottawa funds technical studies for business retrofits
For Ottawa businesses, the opportunity to improve building performance has never been greater. Energy retrofits can cut emissions, strengthen operations, extend the life of assets, reduce operating costs, and position
In a tough economy, investing in community is more important than ever
When finances are tight, it might seem counterintuitive to give back, but supporting our most vulnerable neighbours this holiday season can actually help businesses weather their own challenges. At United
Earlier this year, the company’s auditors expressed concern about the firm’s ability to continue operating amid its mounting debt.
Annidis’ stock price was flat at one cent on the TSX Venture Exchange on Monday.
